Skip to Main Content
Services Talent Knowledge
Site Search
Menu

News

July 29, 2024

Janice Grubin Joins ABA Commission on Sexual Orientation and Gender Identity

Janice Grubin, partner and Restructuring, Bankruptcy & Creditors’ Rights Practice Area co-chair, has joined the American Bar Association (ABA) Commission on Sexual Orientation and Gender Identity (SOGI). The commission works to secure for lesbian, gay, bisexual, and transgender persons full and equal access to and participation in the ABA, the legal profession, and the justice system. 

Janice was a recipient of the ABA SOGI’s 2024 Stonewall Award, which recognizes those lawyers, members of the judiciary, and legal academia who have effected real change to remove barriers on the basis of sexual orientation, gender identity, or gender expression in the legal profession and the world, nation, state, and/or locale and to recognize those who have championed diversity for the LGBT community, both within the legal profession and impacting the greater human universe.

In addition to her legal practice at Barclay Damon, Janice is a founding member of the firm’s LGBTQIA+ Employee Affinity Network. She is the first vice president and a board member of the LGBT Bar Association of Greater New York and has served as the chair and co-chair of the organization’s Judiciary Committee for more than 12 years.
 

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Massachusetts Federal Court Permits Sharing Clause in Protective Order in Products Liability Case

Alerts

NYS Court of Appeals Holds That Parent May Not Recover for Emotional Injuries in Prenatal-Injury Case

Alerts

Smarter Inventory Management for Pharmacies: Navigating Online Marketplace Compliance

Alerts

Emergency Wine Run, Now Legal: New York State Opens Retail-to-Retail Sales

Alerts

California's Updated Privacy Regulations: Automated Decisionmaking Technology, Cybersecurity Audits, and Risk Assessments, Part 1

Alerts

Pharmacies on High Alert: Optum Rx's 25-Percent Therapeutic-Class Cap Creates Major Legal, Operational, and Competitive Risks